Dark

Check out our API

PTE
PolarityTE, Inc. Common Stock
stock NASDAQ

Inactive

Jun 15, 2023

0.2410USD-0.823%(-0.0020)8,503,338

Pre-market

Dec 31, 1969 7:00:00 PM EST

0.00USD-100.000%(-0.24)0

After-hours

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 21, 2022

05:13AM EST PolarityTE Receives Notice Of Allowance For US Patent Application 'Methods for Development & Use of Minimally Polarized Function Cell Micro-Aggregate Units in Tissue Applications Using LGR4, LGR5 & LGR6 Expressing Epithelial Stem Cell' Benzinga

Jan 18, 2022

08:57AM EST PolarityTE Inc. (PTE), a company focused on regenerative tissue products and biomaterials, said on Tuesday that it has received FDA clearance to commence the first of two planned phase III trials of SkinTE to treat chronic cutaneous ulcers. RTTNews

08:08AM EST PolarityTE Announces U.S. FDA Approval Of IND For Pivotal Phase 3 Study Of SkinTE To Support Chronic Cutaneous Ulcer Indication Benzinga

08:02AM EST PolarityTE : FDA Approves IND For Pivotal Phase 3 Study Of SkinTE To Support Chronic Cutaneous Ulcer Indication RTTNews

08:02AM EST PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of PR Newswire

Jan 3, 2022

07:21AM EST The following are some of the stocks making big moves in Monday's pre-market trading (as of 07.15 A.M. ET). RTTNews

Dec 20, 2021

08:39AM EST PolarityTE, Inc. (PTE), a developer of regenerative tissue products and biomaterials, said on Monday that it has filed its complete response to the U.S. Food and Drug Administration's or FDA's clinical hold correspondence for its Investigational New Drug or IND application for SkinTE with a proposed indication for chronic cutaneous ulcers. RTTNews

08:05AM EST PolarityTE Submits Complete Response To FDA's Clinical Hold Correspondence For SkinTE IND RTTNews

08:03AM EST PolarityTE Announces Submission Of Complete Response To FDA's Clinical Hold Correspondence For SkinTE Investigational New Drug Application Benzinga

08:01AM EST PolarityTE Announces Submission of Complete Response to FDA's Clinical Hold PR Newswire

Nov 19, 2021

04:45PM EST Polarity Shares Spike To $6.90/Share Following Earlier Seeking Alpha Blog Post From Contributor Called 'PolarityTE: All Or Nothing' Benzinga

Nov 18, 2021

10:00AM EST APPH, PTE & HYZN Class Action Reminders: GlobeNewswire Inc

Nov 10, 2021

07:26AM EST PolarityTE Q3 EPS $(0.09) Beats $(0.12) Estimate, Sales $1.12M Beat $810.00K Estimate Benzinga

07:02AM EST PolarityTE Q3 Loss/shr Narrows To $0.01 From $0.18 Last Year RTTNews

07:02AM EST PolarityTE Reports Third Quarter Financial Results and Provides Business Update PR Newswire

04:09AM EST Earnings Scheduled For November 10, 2021 Benzinga

Nov 1, 2021

03:23PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Oct 28, 2021

08:02AM EDT PolarityTE to Report Third Quarter Financial Results on November 10, 2021 PR Newswire

Oct 11, 2021

04:30PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Oct 7, 2021

08:27AM EDT Providing an update regarding the FDA hold on its Investigational New Drug Application (IND) for SkinTE on Thursday, biotechnology company PolarityTE, Inc. (PTE) said it has developed a strong a plan to address the issues FDA identified and is currently working diligently to prepare a complete response. RTTNews

08:13AM EDT UPDATE: PolarityTE Says Co. Has Informally Engaged FDA On Certain Points Raised Related To SkinTE Proposed Potency Assays, Sees Opportunity For Added Guidance From FDA Prior To Submitting Complete Response Benzinga

08:12AM EDT PolarityTE Says 'has developed a strong a plan to address the issues FDA identified' Related To Clinical Hold For Its SkinTE New Drug Application Benzinga

08:06AM EDT PolarityTE Says Strongly Believe In Potential For SkinTE In Chronic Cutaneous Ulcers RTTNews

08:01AM EDT PolarityTE Provides Update on Investigational New Drug Application PR Newswire

Oct 3, 2021

08:55PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Sep 30, 2021

11:18AM EDT How Bad Are PolarityTE's Earnings? | Return On Capital Employed Benzinga

Sep 27, 2021

09:47PM EDT POLARITYTE ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against PolarityTE, Inc. and Encourages Investors to Contact the Firm Business Wire

10:46AM EDT Gainey McKenna & Egleston announces that a class action lawsuit has been filed against PolarityTE, Inc. (Polarity or the Company) (NASDAQ: PTE) in the United States District Court for the District of Utah on behalf of those who purchased PolarityTE securities between April 30, 2020 and August 23, 2021, both dates inclusive (the Class Period). GlobeNewswire Inc

Sep 24, 2021

11:10PM EDT Pomerantz Law Firm Announces the Filing of a Class Action Against PolarityTE, PR Newswire

Sep 7, 2021

08:00AM EDT PolarityTE to Attend H.C. Wainwright 23rd Annual Global Investment Conference and 2021 Cantor Virtual Global Healthcare Conference Business Wire

Sep 2, 2021

08:32AM EDT PolarityTE, Inc. (PTE) announced Thursday the appointment of Richard Hague as Chief Executive Officer, the election of David Seaburg to the Board of Directors, and the appointment of Ryan Mathis as Chief Medical Officer. RTTNews

08:06AM EDT PolarityTE Names Richard Hague CEO; Elects David Seaburg To Board RTTNews

08:06AM EDT PolarityTE Names Richard Hague CEO, David Seaburg Chair Of Strategic Review Committee Benzinga

08:00AM EDT PolarityTE Appoints Richard Hague as Chief Executive Officer and Elects David Seaburg to Board of Directors and Chair of Strategic Review Committee Business Wire

Aug 31, 2021

10:11PM EDT Pomerantz LLP is investigating claims on behalf of investors of PolarityTE, Inc. (PolarityTE or the Company) (NASDAQ:PTE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Aug 24, 2021

08:40AM EDT Biotechnology company PolarityTE, Inc. (PTE) announced Tuesday that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the study proposed in its Investigational New Drug Application (IND) for SkinTE with a proposed indication for chronic cutaneous ulcers. The IND application was filed on July 23, 2021. RTTNews

08:19AM EDT PolarityTE Receives FDA Notice The Study Proposed In THE IND For SkinTE Has Been Placed On Clinical Hold Benzinga

08:10AM EDT PolarityTE Says Study Proposed In The IND Has Been Placed On Clinical Hold RTTNews

08:00AM EDT PolarityTE Provides Update on U.S. FDA Investigational New Drug Application for SkinTE(r) Business Wire

Aug 12, 2021

04:17PM EDT PolarityTE Q2 EPS $(0.06) Beats $(0.10) Estimate, Sales $2.54M Miss $3.19M Estimate Benzinga

04:04PM EDT PolarityTE Q2 Loss/share $0.04 Vs. Loss $0.33 Year Ago RTTNews

04:00PM EDT PolarityTE Reports Second Quarter Financial Results and Provides Business Update Business Wire

08:09AM EDT The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma Benzinga

04:14AM EDT Earnings Scheduled For August 12, 2021 Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Jul 29, 2021

08:00AM EDT PolarityTE to Report Second Quarter Financial Results on August 12, 2021 Business Wire

Jul 28, 2021

11:04AM EDT PolarityTE's SkinTE Meets Primary, Secondary Endpoint Goals In Diabetic Foot Ulcer Trial Benzinga

09:13AM EDT PolarityTE Inc. (PTE) said that SkinTE met primary and secondary endpoints in final analysis from diabetic foot ulcer trial. RTTNews

08:06AM EDT PolarityTE Says SkinTE Met Primary And Secondary Endpoints In Final Analysis From Diabetic Foot Ulcer Trial RTTNews

08:05AM EDT SkinTE Announces Final Data From Trial Evaluating SkinTE In Diabetic Foot Ulcer Treatment; Trial Met Primary Endpoint And Secondary Endpoint Benzinga

08:00AM EDT SkinTE(r) Met Primary and Secondary Endpoints in Final Analysis from Diabetic Foot Ulcer Trial Business Wire

Jul 26, 2021

08:52AM EDT PolarityTE Inc. (PTE) said that it has submitted an investigational new drug application or IND to the United States Food and Drug Administration, seeking authorization to commence a clinical trial to evaluate its SkinTE product for the proposed indication of treatment of chronic cutaneous ulcers. RTTNews

08:18AM EDT PolarityTE Submits Investigational New Drug Application For SkinTE In Chronic Cutaneous Ulcers Benzinga

08:04AM EDT PolarityTE Submits IND Application For SkinTE In Chronic Cutaneous Ulcers RTTNews

08:00AM EDT PolarityTE Submits Investigational New Drug Application for SkinTE(r) in Chronic Cutaneous Ulcers Business Wire

Jul 16, 2021

10:56AM EDT PolarityTE Issues Statement About Potential Ticker Symbol Confusion Benzinga

Jul 12, 2021

08:06AM EDT PolarityTE Receives Notice of Allowance for Chinese Patent Benzinga

May 19, 2021

04:19PM EDT PolarityTE Form4 Shows Insider Peter A Cohen Bought 265,000 Shares Of Common Stock At $0.98 Per Share For A Total Cost Of $259,382 Benzinga

May 18, 2021

08:43AM EDT Axogen To Stop Commercial Sales Of Avive Soft Tissue Membrane Pending Discussions With FDA Benzinga

May 14, 2021

03:09PM EDT Mid-Afternoon Market Update: Dow Jumps 400 Points; CorMedix Shares Slide Benzinga

07:59AM EDT The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts Benzinga

07:08AM EDT PolarityTE Stock Drops On Wider Than Expected Q1 Loss, SkinTE Transitions To BLA Pathway Benzinga

May 13, 2021

04:10PM EDT PolarityTE Q1 Loss/share $0.24 Vs. Loss $0.39 Year Ago RTTNews

04:02PM EDT PolarityTE Q1 EPS $(0.24) Misses $(0.12) Estimate, Sales $4.71M Beat $3.30M Estimate Benzinga

04:00PM EDT PolarityTE Reports First Quarter Results and Provides Business Update Business Wire

08:10AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use Benzinga

04:15AM EDT Earnings Scheduled For May 13, 2021 Benzinga

May 10, 2021

10:27AM EDT PolarityTE Inc. (PTE) said that a multi-center randomized controlled trial evaluating treatment of Diabetic Foot Ulcers with SkinTE plus standard of care compared to standard of care alone met the primary endpoint of wound closure at 12 weeks and secondary endpoint of Percent Area Reduction or PAR at 12 weeks. RTTNews

09:07AM EDT PolarityTE Stock Jumps As SkinTE Aces Diabetic Foot Ulcer Trial Benzinga

08:22AM EDT PolarityTE Announces Trial Evaluating Treatment Of Diabetic Foot Ulcers With SkinTE Plus Standard Of Care Met Primary And Secondary Endpoint Benzinga

08:16AM EDT PolarityTE Says Diabetic Foot Ulcer Trial Met Primary And Secondary Endpoint RTTNews

08:05AM EDT PolarityTE Announces Trial Evaluating Treatment Of Diabetic Foot Ulcers With SkinTE Plus Standard Of Care Met Primary and Secondary Endpoint Benzinga

08:00AM EDT PolarityTE Announces Diabetic Foot Ulcer Trial Met Primary and Secondary Endpoint Business Wire

May 3, 2021

08:00AM EDT PolarityTE to Report First Quarter Financial Results on May 13, 2021 Business Wire

Mar 30, 2021

08:06AM EDT The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings Benzinga

07:35AM EDT Recap: PolarityTE Q4 Earnings Benzinga

07:34AM EDT Polarity TE Inc. (PTE) Tuesday reported a narrower loss for the full year on revenue growth. RTTNews

07:21AM EDT PolarityTE Q4 Sales $3.59M Beat $2.90M Estimate Benzinga

07:05AM EDT PolarityTE 2020 Net Loss $42.85 Mln Vs Net Loss $92.49 Mln Last Year RTTNews

07:00AM EDT PolarityTE Reports Fourth Quarter and Fiscal Year 2020 Results Business Wire

04:04AM EDT Earnings Scheduled For March 30, 2021 Benzinga

Mar 29, 2021

10:07AM EDT PolarityTE's Earnings Outlook Benzinga

Mar 27, 2021

01:01PM EDT The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week Benzinga

Mar 10, 2021

08:00AM EST PolarityTE to Report Fiscal Year 2020 Financial Results on March 30, 2021 Business Wire

Mar 2, 2021

08:00AM EST PolarityTE to Present at the H.C. Wainwright Global Life Sciences Virtual Conference Business Wire

Mar 1, 2021

08:12PM EST Pioneering Technology Corp. Q1 Net Loss $673,435 Vs Net Income $324,733 In Prior Year RTTNews

Feb 10, 2021

08:15AM EST PolarityTE Offers Regulatory Update; Highlights Completion Of Enrollment In Diabetic Foot Ulcer Randomized Trial; Dismissal Of Class Action Suit Benzinga

08:00AM EST PolarityTE Provides Corporate Update Business Wire

Feb 4, 2021

07:22AM EST The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs Benzinga

Feb 3, 2021

04:31PM EST PolarityTE Announces That It Received Allowance For An Additional U.S. Patent Benzinga

04:15PM EST PolarityTE Receives Allowance for Additional U.S. Patent Business Wire

03:08PM EST PolarityTE Shares Spike To Session High; US Patent & Trademark Office For 'METHODS RELATED TO MINIMALLY POLARIZED FUNCTIONAL UNITS' Benzinga

Feb 2, 2021

08:29AM EST Gatemore Capital Management Gatemore Capital Management Now Controls 3.7% Of The Common Stock Of PolarityTE, Inc On A Fully Diluted Basis Benzinga

Jan 29, 2021

01:40AM EST Pioneering Technology FY Loss Per Share $0.02 Vs Loss Of $0.07 Last Year RTTNews

Jan 22, 2021

08:51AM EST PolarityTE Reports Exercise Of Warrants For Gross Proceeds Of $7.67 mln RTTNews

08:45AM EST PolarityTE, Inc. Announces Exercise of Warrants for Gross Proceeds of $7.67 Million Business Wire

Jan 21, 2021

08:31AM EST PolarityTE Reports Completion Of Target Enrollment In Diabetic Foot Ulcer Trial RTTNews

08:07AM EST PolarityTE Announces Completion Of Target Enrollment In Diabetic Foot Ulcer Trial; Co Expects To Release Topline Data Spring 2021 Benzinga

08:00AM EST PolarityTE Announces Completion of Target Enrollment in Diabetic Foot Ulcer Trial Business Wire

Jan 14, 2021

04:06PM EST PolarityTE Announces Closing of $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Business Wire

Jan 12, 2021

08:16AM EST The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue Benzinga

07:07AM EST PolarityTE Announces $10M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Benzinga

07:04AM EST PolarityTE Announces $10.0 Mln Registered Direct Offering PricedAt-The-Market Under Nasdaq Rules RTTNews

07:00AM EST PolarityTE Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Business Wire

Jan 11, 2021

08:34AM EST PolarityTE Forms Strategic Review Committee - Quick Facts RTTNews

08:06AM EST PolarityTE Forms Strategic Review Committee With View To Enhancing Shareholder Value RTTNews

08:00AM EST PolarityTE Announces Formation of Strategic Review Committee Business Wire

Jan 8, 2021

10:21AM EST Looking Into PolarityTE's Return On Capital Employed Benzinga

Jan 5, 2021

08:00AM EST PolarityTE to Present at the H.C. Wainwright Virtual Bioconnect 2021 Conference Business Wire

Dec 28, 2020

08:40AM EST UPDATE: Gatemore Capital Recommends PolarityTE Declassify Board, Grant Firm Access To Books, Form Strategic Alternative Committee Benzinga

08:39AM EST PolarityTE 5.3% Shareholder, Gatemore Capital, Sends Letter To PolarityTE Chair Benzinga

Dec 22, 2020

08:04AM EST PolarityTE Announces $8.0 Mln Registered Direct Offering Priced At-The-Market Under Nasdaq Rules RTTNews

08:01AM EST PolarityTE Announces $8M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Benzinga

08:00AM EST PolarityTE Announces $8.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Business Wire

Nov 30, 2020

08:10AM EST PolarityTE Receives Allowance For US Patent Covering 'methods of making compositions for regenerating functional skin tissue using the Company's minimally polarized functional unit (MPFU) technology.' Benzinga

08:07AM EST PolarityTE Reports U.S. PTO Issued A Notice Of Allowance For U.S. Application No. 14/954,335 RTTNews

08:00AM EST PolarityTE Receives Allowance for First U.S. Patent Business Wire

Nov 24, 2020

08:13AM EST The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia Benzinga

08:12AM EST PolarityTE Reports Dismissal With Prejudice Of Consolidated Class Action Suit Filed In US District Court For Utah Under Securities Litigation Benzinga

08:00AM EST PolarityTE Announces Dismissal of Securities Class Action Complaint with Prejudice Business Wire

Nov 23, 2020

03:49PM EST Why PolarityTE's Stock Is Trading Lower Today Benzinga

Nov 19, 2020

10:56AM EST PolarityTE Shares Spike To Session High, Now Up 20%; Traders Circulate US Patent Trademark Office Patent Center Listing For Co.'s 'Methods for Development and Use of Minimally Polarized Function Cell Micro-Aggregate Units in Tissue Applications' Benzinga

Nov 10, 2020

08:40AM EST The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies Benzinga

Nov 9, 2020

07:24AM EST Recap: PolarityTE Q3 Earnings Benzinga

07:16AM EST PolarityTE Q3 EPS $(0.18) Beats $(0.21) Estimate, Sales $3.34M Beat $2.97M Estimate Benzinga

07:04AM EST PolarityTE Q3 Loss Per Share $0.18 Vs Loss $0.87 Last Year RTTNews

07:00AM EST PolarityTE Reports Third Quarter 2020 Results Business Wire

04:13AM EST Earnings Scheduled For November 9, 2020 Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 2, 2020

08:08AM EST PolarityTE Announces Successful Completion Of Initial Pre-IND Interaction With FDA For SkinTE; Co. Plans To Submit An IND Submission For One Or More Indications In Second Half Of 2021 Benzinga

08:08AM EST PolarityTE Announces Successful Completion Of Initial Pre-IND Interaction With FDA For SkinTE RTTNews

08:00AM EST PolarityTE Announces Successful Completion of Initial Pre-IND Interaction with U.S. Food and Drug Administration for SkinTE(r) Business Wire

Oct 26, 2020

08:00AM EDT PolarityTE to Report Third Quarter 2020 Financial Results on November 9, 2020 Business Wire

Sep 29, 2020

08:05AM EDT PolarityTE Announces Termination Of Shareholder Rights Plan RTTNews

Sep 21, 2020

08:15AM EDT PolarityTE Receives NIH Grant For Point-of-Care Device To Treat Chronic Wounds Benzinga

08:05AM EDT PolarityTE Secures NIH Grant For A Point-of-Care Device To Treat Chronic Wounds RTTNews

08:00AM EDT PolarityTE Receives NIH Grant for a Point-of-Care Device to Treat Chronic Wounds Business Wire

Sep 16, 2020

08:14AM EDT PolarityTE Reports SkinTE Health Economics-DFU Interim Analysis Data Showed Potential For Cost Savings, Improved Wound Closure Benzinga

08:00AM EDT SkinTE(tm) Health Economics-DFU Interim Analysis Data Demonstrates Potential for Cost Savings and Improved Wound Closure Business Wire

Sep 14, 2020

11:15AM EDT PolarityTE shares are trading higher after the company announced it expects Q3 sales to meet or exceed previously issued guidance of $2.7 million to $3.2 million, versus the $2.85 million estimate. Benzinga

08:07AM EDT PolarityTE Expects Q3 Sales To Meet Or Exceed Previous Issued Guidance of $2.7M-$3.2M Vs. $2.85M Est. Benzinga

08:04AM EDT PolarityTE Sees Q3 Revenues To Likely Meet Or Exceed Top End Of Previous Range Of $2.7 Mln To $3.2 Mln RTTNews

08:00AM EDT PolarityTE Expects Third Quarter Revenue to Meet or Exceed High-End of Guidance Business Wire

Sep 8, 2020

08:39AM EDT PolarityTE Unit Partners With Co-Diagnostics To Expand RTTNews

08:10AM EDT Arches Research Enters Strategic Partnership With Co-Diagnosticsto Expand COVID-19 Testing Operations RTTNews

08:08AM EDT Co-Diagnostics Agrees With Arches Research To Expand COVID-19 Testing Services RTTNews

08:03AM EDT Co-Diagnostics, Inc. Enters Into Agreement With Arches Research To Expand COVID-19 Testing Services Benzinga

08:02AM EDT Co-Diagnostics, Inc. Enters into Agreement with Arches Research to Expand PR Newswire

08:00AM EDT PolarityTE Announces Strategic Partnership with Co-Diagnostics to Expand COVID-19 Testing Platform Business Wire

Aug 6, 2020

11:20AM EDT PolarityTE Earlier Reported Q2 EPS $(0.33) Beats $(0.38) Estimate, Sales $2.27M Beat $830.00K Estimate Benzinga

07:57AM EDT The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO Benzinga

07:04AM EDT PolarityTE Q2 Loss Per Share $0.33 Vs Loss $0.92 Last Year RTTNews

07:00AM EDT PolarityTE Reports Second Quarter 2020 Results Business Wire

Jul 30, 2020

08:00AM EDT PolarityTE Announces the Addition of Clinical Development and Regulatory Affairs Executive Jessica Shen, MD, MS to Board of Directors Business Wire

Jul 29, 2020

08:00AM EDT PolarityTE to Report Second Quarter 2020 Financial Results on August 6, 2020 Business Wire

Jul 24, 2020

08:30AM EDT PolarityTE Inc. (PTE) announced positive results from a protocol-specified interim analysis of the first 50 patients enrolled in a multi-center randomized controlled trial evaluating treatment of Diabetic Foot Ulcers with SkinTE plus standard of care or SOC vs SOC alone. RTTNews

08:05AM EDT UPDATE: PolarityTE On Secondary Endpoint: Percent Area Reduction Was Greater With SkinTE SOC Plus SOC vs SOC Alone, Was Statistically Significance Benzinga

08:04AM EDT UPDATE: PolarityTE On Primary Endpoint: 72% Of Patients Treated With SkinTE Plus SOC Achieved Wound Closure By 12 Weeks vs 32% Of Patients Treated With SOC Alone Benzinga

08:04AM EDT PolarityTE Reports Results From Protocol-Specified Interim Analysis Of First 50 Patients Enrolled In Trial For SkinTE Diabetic Foot Ulcer Benzinga

08:02AM EDT PolarityTE Announces Positive Top-Line Data From Interim Analysis Of SkinTE Diabetic Foot Ulcer Trial RTTNews

08:00AM EDT PolarityTE Announces Positive Top-Line Data from Interim Analysis of SkinTE(tm) Diabetic Foot Ulcer Trial Business Wire

Jul 20, 2020

08:06AM EDT PolarityTE Announces Interim Data From Diabetic Foot Ulcer Trial Will Presented At Symposium On Advanced Wound Care To Be Held July 24-26, 2020 Benzinga

08:05AM EDT PolarityTE Says Interim Data From Diabetic Foot Ulcer Trial Will Be Presented At SAWC To Be Held July 24-26 RTTNews

08:00AM EDT PolarityTE Announces Interim Data from Diabetic Foot Ulcer Trial will be Presented at Symposium on Advanced Wound Care to be Held July 24-26, 2020 Business Wire

Share